Hydrocortisone

Intervention Approved 1951

3 papers1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country
0 on aging of 224 trials, 71 with no results posted

Funder: Universidad Autónoma del Estado de México

Humans1
Cells2

Outcomes

Replicative lifespan extension

upin human cells1

1 study

Hydrocortisone improves replicative lifespan extension in human cells.
“Hydrocortisone showed the highest RLE values among six hormones, followed by three plant extracts, sodium ascorbate and quercetin.”
Cellsin HDFa cellsdermis0.01-100 μM
Quantification of In Vitro Replicative Lifespan Elongation Activity of Hormones, Antioxidants, Plant Extract and Bacterial Exudate by Updated "Overlay Method"
Medicines (Basel, Switzerland)30 Mar 2026

Trials

0 on aging of 224

Approved

FDA Hydrocortone
21 Dec 1951Discontinued
FDA Hydrocortone
5 Aug 1952Discontinued
FDA Cortef
15 Dec 1952Adrenal Hyperplasia, Congenital, Arthritis, Rheumatoid, Dermatitis, Erythema, cancer, osteoarthritis, psoriasis, systemic lupus erythematosus, psoriatic arthritis, allergic rhinitis, ankylosing spondylitis, pemphigus, dermatomyositis, juvenile rheumatoid arthritis, acute gouty arthritis, Hypercalcemia, synovitis, post-traumatic osteoarthritis, mycosis
FDA Cortef Acetate
28 Jul 1953Discontinued
FDA Cortril
3 Dec 1953Discontinued
FDA Hydrocortisone
19 Jan 1955Discontinued

All 27

FDA Solu-Cortef
27 Apr 1955Adrenal Hyperplasia, Congenital, Asthma, Colitis, Ulcerative, Dermatitis, Dermatitis, Atopic, Erythema, Purpura, cancer, anemia, pemphigus, Hypercalcemia, hemolytic anemia, mycosis
FDA Cortef
10 May 1955Discontinued
FDA Hydrocortone
8 Jun 1960Discontinued
FDA Cortenema
12 Jan 1966Colitis, Ulcerative
FDA Cortril
24 May 1972Discontinued
FDA Westcort
17 Mar 1978Discontinued
FDA Cortifoam
12 Feb 1982Cortifoam ® is indicated as adjunctive therapy in the topical treatment of ulcerative proctitis of the distal portion of the rectum in…
FDA Westcort
8 Aug 1983Discontinued
FDA Hydrocortisone Acetate
25 Jun 1997Discontinued
EMA Plenadren
3 Nov 2011Adrenal Insufficiency
EMA Alkindi
9 Feb 2018Adrenal Insufficiency
FDA Alkindi Sprinkle
29 Sep 2020ALKINDI SPRINKLE is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency. ALKINDI SPRINKLE is a…
EMA Efmody
27 May 2021Adrenal Hyperplasia, Congenital
FDA Khindivi
28 May 2025KHINDIVI is indicated as replacement therapy in pediatric patients 5 years of age and older with adrenocortical insufficiency. KHINDIVI is…
FDA Hydrocortone
Discontinued
FDA Cortril
Discontinued
FDA Cortef Acetate
Discontinued
FDA Cort-Dome
Discontinued
FDA Cortril
Discontinued
FDA Cortef
Discontinued
FDA Cort-Dome
Discontinued

Repurposing

Depression
Phase 4Results posted2 trials
Coronary artery disease
Phase 4Completed1 trial
Hyperglycemia
Phase 4Completed1 trial
COVID-19
Phase 3Completed1 trial
Sepsis
Phase 4Terminated13 trials
Post-traumatic stress disorder
Phase 4Results posted2 trials

40 of 70

Fatigue
Phase 4Status unknown1 trial
Pancreatitis
Phase 4Recruiting2 trials
Leukemia
Phase 3Completed9 trials
Critical illness
Phase 4Terminated3 trials
Hypotension
Phase 3Completed1 trial
Lymphoma
Phase 3Completed2 trials
Thyroid disease
Phase 4Recruiting1 trial
Thrombocytopenia
Phase 3Status unknown1 trial
Crohn's disease
Phase 4Status unknown1 trial
Cardiotoxicity
Phase 3Completed1 trial
Septic shock
Phase 4Recruiting12 trials
Acute lung injury
Phase 3Terminated1 trial
Cardiogenic shock
Phase 3Completed1 trial
Hypoxia
Phase 3Completed1 trial
Arthralgia
Phase 3Recruiting1 trial
Community-acquired pneumonia
Phase 3Completed1 trial
Mania
Phase 3Results posted1 trial
Rheumatic diseases
Phase 4Completed1 trial
Alopecia areata
Phase 3Completed1 trial
Premature birth
Phase 3Results posted3 trials
Shock
Phase 4Results posted5 trials
Eczema
Phase 3Results posted2 trials
Burns
Phase 4Completed1 trial
Mitral valve insufficiency
Phase 4Completed1 trial
Pancreatic neoplasms
Phase 4Active, not recruiting1 trial
Postoperative pain
Phase 4Completed1 trial
Viral pneumonia
Phase 3Terminated1 trial
Addison's disease
Phase 4Completed5 trials
Edema
Phase 4Completed2 trials
Candidiasis
Phase 4Results posted1 trial
Pruritus
Phase 3Results posted1 trial
Fibrosis
Phase 2Status unknown1 trial
Down syndrome
Phase 2Active, not recruiting2 trials
Neoplasm
Phase 2Results posted2 trials

In trials

Precursor cell lymphoblastic leukemia lymphoma
Phase 4Completed38 trials
Leukemia, Biphenotypic, Acute
Phase 4Recruiting13 trials
Respiratory distress syndrome
Phase 4Status unknown3 trials
Fistula
Phase 4Recruiting2 trials
Leukemia, Myeloid, Acute
Phase 3Recruiting13 trials
Prostatic Neoplasms
Phase 3Completed12 trials

All 28

Burkitt Lymphoma
Phase 3Results posted11 trials
Bronchopulmonary Dysplasia
Phase 3Results posted4 trials
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Phase 3Active, not recruiting4 trials
Psoriasis Vulgaris
Phase 3Results posted3 trials
Heart Arrest
Phase 3Completed2 trials
Hemostatic Disorders
Phase 3Completed2 trials
Human influenza
Phase 3Terminated1 trial
Ocular inflammation
Phase 3Recruiting1 trial
Otitis externa
Phase 3Completed1 trial
Recurrence
Phase 2Recruiting7 trials
Lymphoma, large b-cell, diffuse
Phase 2Results posted4 trials
T-Cell Lymphoma
Phase 2Recruiting3 trials
Hodgkin Disease
Phase 2Results posted2 trials
Leukemia, Myelomonocytic, Juvenile
Phase 2Active, not recruiting2 trials
T-Cell Leukemia
Phase 2Terminated2 trials
Breast neoplasm
Phase 2Completed1 trial
Graft vs host disease
Phase 2Results posted1 trial
Hemophagocytic lymphohistiocytosis
Phase 2Results posted1 trial
Sleep Restriction
Phase 1Active, not recruiting2 trials
Blood pressure
Early phase 1Completed1 trial
Fasting
Early phase 1Completed1 trial
Starvation
Early phase 1Completed1 trial

Stopped

NCT01150409TerminatedSepsis
Difficulty in recruiting eligible subjects
NCT03335124TerminatedSepsis
Due to insufficient recruitment
NCT00705822TerminatedProstatic Neoplasms
low recruitment rate
NCT01014364TerminatedAcute lung injury
the H1N1 pandemic is now over, and fewer cases than expected were observed
NCT02433483TerminatedMyelodysplastic syndrome
The study was closed due to poor accrual and because of competing protocols.
NCT02535806TerminatedRecurrence
Funding source discontinued

All 9

NCT00482053TerminatedLymphoma, large b-cell, diffuse
Low accrual
NCT02518750Terminatednon-Hodgkin lymphoma
Due to slow accrual
NCT03261336TerminatedCastration-resistant prostate cancer
can not meet enrollment